Human Fc gamma RIIIB / CD16b (NA1) Protein, His Tag (SPR & BLI & MALS verified)
分子別名（Synonym）
Fc gamma RIIIB，FCGR3B，CD16b (NA1)，CD16B，FCG3B，FCGR3，FCG3，IGFR3
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human CD16b (NA1), His Tag (CDB-H5227) is expressed from human HEK293 cells. It contains AA Gly 17 - Ser 200 (Accession # AAA35881.1). The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106.
Predicted N-terminus: Gly 17
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.8 kDa. The protein migrates as 35-45 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景（Background）
CD16是一種低親和力Fc受體，已被鑒定為Fc受體FcγRIIIa（CD16a）和FcγRIII/b（CD16b）。這些受體與IgG抗體的Fc部分結(jié)合。CD16由兩個不同的高度同源基因以細(xì)胞類型特異的方式編碼。CD16存在于自然殺傷細(xì)胞、中性粒細(xì)胞、多形核白細(xì)胞、單核細(xì)胞和巨噬細(xì)胞的表面。CD16B也被稱為FCGR3B和FCG3B，由多形核白細(xì)胞（中性粒細(xì)胞）和受刺激的嗜酸性粒細(xì)胞特異性表達(dá)。CD16B是免疫球蛋白γFc區(qū)的低親和力受體。FCGR3B結(jié)合復(fù)合或聚集的IgG以及單體IgG。與III-A相反，FCG3B不能介導(dǎo)抗體依賴性細(xì)胞毒性和吞噬作用。CD16B可能作為外周循環(huán)中免疫復(fù)合物的陷阱，不會激活中性粒細(xì)胞。
關(guān)鍵字： Fc gamma RIIIB;CD16b蛋白;FCGR3B;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。